Drugs / Racemic Epinephrine
Racemic Epinephrine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04688346 | Jun → Nov 2019 | — | University of Washington | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02724761 | Sep 2016 → Jun 2018 | voice disorders | Andrew Chung | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | racemic epinephrine | “In the intervention group, hemostasis will be achieved by using two racemic epinephrine HCl pellets (HemeRX, Racellet #3, Sprig Oral Health Technologies, Inc. Loomis, CA).” NCT04688346 ↗ |
| Known as | HemeRX | “In the intervention group, hemostasis will be achieved by using two racemic epinephrine HCl pellets (HemeRX, Racellet #3, Sprig Oral Health Technologies, Inc. Loomis, CA).” NCT04688346 ↗ |
| Known as | Racellet #3 | “In the intervention group, hemostasis will be achieved by using two racemic epinephrine HCl pellets (HemeRX, Racellet #3, Sprig Oral Health Technologies, Inc. Loomis, CA).” NCT04688346 ↗ |
| Known as | racemic epinephrine HCl | “In the intervention group, hemostasis will be achieved by using two racemic epinephrine HCl pellets (HemeRX, Racellet #3, Sprig Oral Health Technologies, Inc. Loomis, CA).” NCT04688346 ↗ |
| Route | Inhaled | “1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery” NCT02724761 ↗ |